

## Pazopanib, Multi-receptor tyrosine kinase inhibitor

Catalog	Unit
TBI2158-5MG	5 mg
TBI2158-25MG	25 mg

### Product Details

**Formal Name:** 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide

**Alternate Names:** GSK-VEG10003; GW786034B

**Molecular Formula:** C<sub>21</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub>S

**Formula Weight:** 437.50

**CAS Number:** 444731-52-6


**Purity:** >98%

**Formulation:** powder

**Solubility:** Soluble in DMSO (up to 16 mg/ml).

**Storage:** -20°C

**Stability:** ≥ 1 year.



### Applications

Multi-receptor tyrosine kinase inhibitor

### Functions

Inhibits multiple receptor tyrosine kinases including VEGFR1,2 and 3 (IC<sub>50</sub>s=10, 30, 47 nM respectively) and PDGFR $\alpha$ ,  $\beta$  and c-Kit (IC<sub>50</sub>s=71, 84, 74 nM respectively) and others such as FGFR. The drug targets both the tumor and endothelial cells in a mouse xenograft model of human multiple myeloma. It reduces joint pain and inhibits cartilage degeneration in rodent osteoarthritis models. VEGF inhibitors such as pazopanib have potential for treatment of neovascular age-related macular degeneration. In clinical use for renal cell carcinoma.

### Application Procedures

First dissolved in DMSO (up to 16 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

**For research use only.**